Activated protein C resistance in anterior ischaemic optic neuropathy

Acta Ophthalmologica Scandinavica

Volumn 82, Issue 2, 2004, Pages 140-143

  Nagy, Valeria ^a   Facsko, Andrea ^a   Takacs, Lili ^a   Balazs, Erzsebet ^a   Berta, Andras ^a   Balogh, Istvan ^a   Edes, Istvan ^a   Czuriga, Istvan ^a   Pfliegler, Gyorgy ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Activated protein C resistance; Leiden mutation; Non arteritic anterior ischaemic optic neuropathy

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; ISCHEMIC OPTIC NEUROPATHY; MALE; MUSCLE HYPERTONIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; STATISTICAL ANALYSIS; VASCULAR DISEASE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; OPTIC NEUROPATHY, ISCHEMIC; POINT MUTATION; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 1942484748     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2004.00226.x     Document Type: Article

References (24)

1. Aparicio C & Dahlbäck B (1996): Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 15: 467-472.
2. Balogh I, Poka R & Pfliegler G (1999): High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary. Thromb Haemost 81: 660-661.
3. Beri M, Klugman MR & Kohler J (1987): Anterior ischemic optic neuropathy VII. Incidence of bilaterality and various influencing factors. Ophthalmol 94: 1020-1028.
4. Bertina RN, Koeleman BPC & Reitsma PH (1994): Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64-67.
5. Cursiefen C, Schönherr U & Grossmann R (1999): Recurrent optic nervehead infarctions associated with combined factor V Leiden and factor II: G20210A-mutation. Acta Ophthalmol Scand 77: 625-627.
6. 506 Q mutation is a common risk factor of venous thrombosis. Thromb Haemost 78: 483-488.
7. Dahlbäck B, Carlson M & Svenson PJ (1993): Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90: 1004-1008.
8. Hayreh SS (1974a): Anterior ischaemic optic neuropathy. II. Fundus on opthalmoscopy and fluorescein angiography. Br J Ophthalmol 58: 964-980.
9. Hayreh SS (1974b): Anterior ischaemic optic neuropathy. Terminology and pathogenesis. Br J Ophthalmol 58: 955-963.
10. Hayreh SS, Joos KM & Long CR (1994): Systemic diseases associated with non-arteritic anterior ischaemic optic neuropathy. Am J Opthalmol 118: 766-780.
11. Hayreh SS, Podhajsky PA & Zimmerman B (1997): Non-arteritic anterior ischaemic optic neuropathy: time of onset of visual loss. Am J Opthalmol 124: 641-647.
12. Kanski JJ (1994): Clinical Ophthalmology. Neuro-Ophthalmology, 3rd edn. Oxford: Butterworth-Heinemann 460-462.
13. Kawasaki A, Purvin AV & Burgett RA (1999): Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 83: 1287-1290.
14. Leiba H, Rachmiel R & Zalish M (2000): Optic nervehead blood flow measurements in non-arteritic anterior ischaemic optic neuropathy. Eye 14: 828-833.
15. Repka MX, Savino PJ & Schatz NJ (1983): Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 94: 478-483.
16. Salomon O, Huna-Baron R & Seligson U (1998): Analysis of prothrombotic and vascular risk factors in patients with non-arteritic anterior ischaemic optic neuropathy. Ophthalmology 106: 739-742.
17. Salomon O, Huna-Baron R & Seligson U (1999): Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye 13: 357-359.
18. Shin SY, Kim DS & Ko MK (1999): Fluorescein angiographic features of chorioideal insufficiency in anterior ischaemic optic neuropathy. Korean J Ophthalmol 13 (2): 100-104.
19. Shimon K, Winder A & Eldor A (1999): Activated protein C resistance in a case of anterior ischaemic optic neuropathy. Ann Ophthalmol 31: 151-152.
20. Shin SY, Kim DS & Ko MK (1999): Fluorescein angiographic features of choroidal insufficiency in anterior ischaemic optic neuropathy. Korean J Ophthalmol 13: 100-104.
21. Srinivarsan S, Fern A & McColl (2001): Reversal of non-arteritic anterior ischaemic optic neuropathy associated with co-existing primary antiphospholipid syndrome and factor V Leiden mutation. Am J Ophthalmol 131: 671-673.
22. Talks SJ, Chong NHV & Dodson PM (1995): Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. Eye 9: 85-88.
23. Vine AK & Samana MM (1997): Screening for resistance to activated protein C and mutant gene for factor V: Q506 in patients with central retinal vein occlusion. Am J Ophthalmol 124: 673-676.
24. Zöller B, Hillap A, Berntorp E & Dahlbäck B (1997): Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 48: 45-58.